7OM5

Anti-EGFR nanobody EgB4

7OM5 の概要

• エントリーDOI: 10.2210/pdb7om5/pdb
• 分子名称: Nanobody EgB4, GLYCEROL, ZINC ION, ... (4 entities in total)
• 機能のキーワード: egfr, nanobody, cancer, signaling, immune system
• 由来する生物種: Lama glama
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 28613.82

構造登録者

Zeronian, M.R.,Janssen, B.J.C. (登録日: 2021-05-21, 公開日: 2022-03-02, 最終更新日: 2024-11-20)

主引用文献

Zeronian, M.R.,Doulkeridou, S.,van Bergen En Henegouwen, P.M.P.,Janssen, B.J.C.
Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
Bmc Mol Cell Biol, 23:12-12, 2022

PubMed Abstract: The epidermal growth factor receptor (EGFR) is involved in various developmental processes, and alterations of its extracellular segment are associated with several types of cancers, in particular glioblastoma multiforme (GBM). The EGFR extracellular region is therefore a primary target for therapeutic agents, such as monoclonal antibodies and variable domains of heavy chain antibodies (VHH), also called nanobodies. Nanobodies have been previously shown to bind to EGFR, and to inhibit ligand-mediated EGFR activation.

PubMed: 35232398
DOI: 10.1186/s12860-022-00412-x

実験手法

X-RAY DIFFRACTION (1.48 Å)